Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Heparin (Pfizer) TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: heparin
Brand name
(ARTG)
: HEPARIN SODIUM 5000IU/5mL (porcine mucous) injection ampouleDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
INDICATIONS AS AT 26 NOVEMBER 2001: Prophylaxis and treatment of thromboembolic disorders such as thrombophlebitis, pulmonary embolism, coronary or venous thrombosis and occlusive vascular disease. As a low-dose regimen for the prevention of thromboembolic complications arising as a result of cardiac and arterial surgery. As an anticoagulant during blood transfusions, extracorporeal circulation, dialysis and other perfusion techniques and in blood samples for laboratory purposes.
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intravenous
- Clear, colourless or straw coloured solution, free from visible impurities.
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Shelf lifetime is 2 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 5mL x 10 pack
- 5mL x 50 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient heparin
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems
Need more information?
These trusted information partners have more on this topic.
Top results
Vaxzevria (AstraZeneca) vaccine and thrombosis with thrombocytopenia (TTS) | Australian Government Department of Health and Aged Care
Thrombosis with thrombocytopenia (TTS) is a rare syndrome that occurred in around 2 to 3 people per 100,000 who were vaccinated with AstraZeneca. AstraZeneca is no longer available in Australia from 21 March 2023.
Read more on Australian Government Department of Health and Aged Care website
Top results
ATAGI statement for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions | Australian Government Department of Health and Aged Care
A statement from the Australian Technical Advisory Group on Immunisation (ATAGI) for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions.
Read more on Australian Government Department of Health and Aged Care website
